P-glycoprotein (Pgp) does not affect the cytotoxicity of flavonoids from Sophora flavescens, which also have no effects on Pgp action

Anticancer Research

Volumn 19, Issue 3 A, 1999, Pages 2035-2040

  Choi, Sang U N ^a   Kim, Kwang Hee ^a   Choi, Eun Jung ^c   Park, Sung Hee ^a   Lee, Chong Ock ^c   Jung, Noh Pal ^b   Yoon, Seuk Keun ^a   Ryu, Shi Yong ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Yonsei University   (South Korea)

^c NONE

Author keywords

Cytotoxicity; Drug resistance; Flavonoids; P glycoprotein; Sophora flavescens

Indexed keywords

FLAVONOID; GLYCOPROTEIN P; KURARINOL; KURARINONE; KUSHENOL K; NORKURARINOL; PACLITAXEL; RHODAMINE 123; SOPHORA FLAVESCENS EXTRACT; SOPHORAFLAVANONE; UNCLASSIFIED DRUG; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CELL MEMBRANE PERMEABILITY; CENTRAL NERVOUS SYSTEM NEOPLASMS; COLORECTAL NEOPLASMS; CYCLOSPORINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLAVONOIDS; FLUORESCENT DYES; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PLANT EXTRACTS; QUINIDINE; RHODAMINE 123; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0032775169     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kang TB and Liang NC: Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells. Biochem Pharmacol 54: 1013-1018, 1997.
2. Lin JK, Chen YC, Huang YT and Lin-Shiau SY: Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcimin, J Cell Biochem 28: 39-48, 1997.
3. Carlson BA, Duhay MM, Sausville EA, Brizuela L and Worland PJ: Flavopriridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973-2978, 1996.
4. Ford JM, Yang JM and Hait WN: P-glycoprotein-mediated multidrug resistance: Experimental and clinical strategies for its reversal. Cancer Treat Res 87: 3-38, 1996.
5. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yegar H and Ling V; P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608-1614, 1991.
6. Linn SC, Giaccone G, van Diest PJ, Blokhuis WM, van der Valk P, van Kalken CK, Kuiper CM, Pinedo HM and Baak JP: Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 6: 679-685, 1995.
7. Lum BL, Gosland MP, Kaubisch S and Sikic BI: Molecular targets in oncology: Implications of the multidrug resistance gene. Pharmacother 13: 88-109, 1993.
8. Schinkel AH, Wagenaar E, Mol CA and van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Clin Inverst 97: 2517-2524, 1996.
9. Ryu SY, Choi SU, Kim SK, No Z, Lee CO, Ahn JW and Kim SH: In vitro antitumour activity of flavonoids from Sophora flavescens. Phytother Res 11: 51-53, 1997.
10. Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD and Tew KD: P-glycoprotein binding and modulation of the multidrug resistant phenotype by estramustine, J Natl Cancer Inst 86: 688-694, 1994.
11. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT and Bates SE: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 46: 627-638, 1994.
12. Tompkins, WAF, Watrach AM, Schmale JD, Schultz RM and Harris JA: Cultural and antigenic properties of newly established cell strains derived from adenocarcinomas of the human colon and rectum. J Natl cancer Inst 52: 1101-1110, 1974.
13. Alvarez M, Raull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates SE and Fojo AT: Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. J Clin Invest 95: 2205-2214, 1995.
14. Choi S-U, Kim NY, Choi EJ, Kim KH, Lee JO. Establishment of doxorubicin-resistant subline derived from HCT15 human colorectal cancer cells. Arch Pharm Res 19: 342-347, 1996.
15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
16. Choi S-U, Lee C-O, Kim K-H, Choi E-J, Park S-H, Shin H-S, Yoo S-E, Jung N-P and Lee B-H: Reversal of multidrug resistance by novel verapamil analogs in cancer cells. Anti-Cancer Drugs 9: 157-165, 1998.
17. Critchfield JW, Welsh CJ, Phang JM and Yeh GC: Modulation of adriamycin accumulation and efflux by flavonoids in HCT15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48: 1437-1445, 1994.
18. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa S, Rumi C and Cianfriglia M: Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34: 459-464, 1994.
19. Castro AF and Altenberg GA: Inhibition of drug transport by genistein in multidnig-resistant cells expressing P-glycoprotein. Biochem Pharmacol 53: 89-93, 1997.
20. Maia RC, Vasconcelos FC, Harab RC, Coelho AM, Dobbin JA and Rumjanek VM: Comparison between anthracyclines and rhodamine-123 accumulation in chronic lymphoid leukemia: effect of cyclosporin A and verapamil. Tumour Biol 19: 41-51, 1998.
21. Petriz J and Garcia-Lopez J: Flow cytometric analysis of p-glycoprotein function using rhodamine 123. Leukemia 11: 1124-1130, 1997.